CellRight Technologies, subsidiary of Tissue Regenix (TRX), signed a long-term, multi-year agreement with Arthrex for distribution of CellRight’s orthobiologic products that have application in spine, trauma, foot/ankle, sports medicine and general ortho procedures.
TRX acquired CellRight Technologies in 3Q17. Combined, the companies offer products for bone and soft tissue regeneration based on CellRight’s human-derived bone grafts and TRX’s dCELL® decellularization platform.
Source: Tissue Regenix
CellRight Technologies, subsidiary of Tissue Regenix (TRX), signed a long-term, multi-year agreement with Arthrex for distribution of CellRight's orthobiologic products that have application in spine, trauma, foot/ankle, sports medicine and general ortho procedures.
TRX acquired CellRight Technologies in 3Q17. Combined, the companies...
CellRight Technologies, subsidiary of Tissue Regenix (TRX), signed a long-term, multi-year agreement with Arthrex for distribution of CellRight’s orthobiologic products that have application in spine, trauma, foot/ankle, sports medicine and general ortho procedures.
TRX acquired CellRight Technologies in 3Q17. Combined, the companies offer products for bone and soft tissue regeneration based on CellRight’s human-derived bone grafts and TRX’s dCELL® decellularization platform.
Source: Tissue Regenix
You are out of free articles for this month
Subscribe as a Guest for $0 and unlock a total of 5 articles per month.
You are out of five articles for this month
Subscribe as an Executive Member for access to unlimited articles, THE ORTHOPAEDIC INDUSTRY ANNUAL REPORT and more.
JV
Julie Vetalice is ORTHOWORLD's Editorial Assistant. She has covered the orthopedic industry for over 20 years, having joined the company in 1999.